Your browser version may not work well with NCBI's Web applications. More information here...
1: Prog Lipid Res. 2002 Sep;41(5):392-406.Click here to read Links

A lipid based depot (DepoFoam technology) for sustained release drug delivery.

Mantripragada S.

SkyePharma Inc., 10450 Science Center Drive, San Diego, CA 92121, USA. sankaram@skyepharma.com

Encapsulation of drugs into multivesicular liposomes (DepoFoam) offers a novel approach to sustained-release drug delivery. While encapsulation of drugs into unilamellar and multilamellar liposomes, and complexation of drugs with lipids, resulted in products with better performance over a period lasting several hours to a few days after intravascular administration, DepoFoam-encapsulation has been shown to result in sustained-release lasting over several days to weeks after non-vascular administration. The routes of administration most viable for delivery of drugs via DepoFoam formulations include intrathecal, epidural, subcutaneous, intramuscular, intra-atricular, and intraocular. DepoFoam particles are distinguished structurally from unilamellar vesicles, multilamellar vesicles, and neosomes in that each particle comprises a set of closely packed non-concentric vesicles. The particles are tens of microns in diameter and have large trapped volume, thereby affording delivery of large quantities of drugs in the encapsulated form in a small volume of injection. A number of methods based on a manipulation of the lipid and aqueous composition can be used to control the rate of sustained-release from a few days to several weeks.

PMID: 12121719 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Cytarabine (Cytosar-U® , DepoCyt® )

    Your doctor has ordered the drug cytarabine to help treat your illness. The drug can be given by injection into a vein or under the skin of your forearm. In special situations, it may be injected into the spinal cord.

  • Source: AHFS Consumer Medication Information